Patents by Inventor John T. Patton, Jr.
John T. Patton, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140178303Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: ApplicationFiled: December 13, 2013Publication date: June 26, 2014Applicant: GLYCOMIMETICS, INC.Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Patent number: 8633303Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: June 21, 2011Date of Patent: January 21, 2014Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Patent number: 8530448Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.Type: GrantFiled: April 2, 2010Date of Patent: September 10, 2013Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Leonard M. Williams
-
Patent number: 8518896Abstract: Methods and medicaments therefor are provided for the treatment of cancers of the blood or a complication therewith in an individual. More specifically, the use of particular glycomimetics for the treatment is described. Methods and medicaments therefor are also provided without regard to cancer type for reducing in an individual the myeloablative bone marrow toxicities of chemotherapy.Type: GrantFiled: June 10, 2009Date of Patent: August 27, 2013Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Theodore A. G. Smith
-
Publication number: 20120329755Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.Type: ApplicationFiled: August 3, 2012Publication date: December 27, 2012Applicant: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar
-
Patent number: 8258290Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.Type: GrantFiled: February 13, 2009Date of Patent: September 4, 2012Assignee: GlycoMimetics, Inc.Inventors: John L Magnani, John T Patton, Jr., Arun K Sarkar
-
Publication number: 20120004190Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: ApplicationFiled: June 21, 2011Publication date: January 5, 2012Applicant: GlycoMimetics, Inc.Inventors: John L. MAGNANI, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Patent number: 7989601Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: April 20, 2010Date of Patent: August 2, 2011Assignee: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Publication number: 20100279958Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.Type: ApplicationFiled: April 2, 2010Publication date: November 4, 2010Applicant: GlycoMimetics, Inc.Inventors: John L. MAGNANI, John T. Patton, JR., Leonard M. Williams
-
Publication number: 20100204170Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: ApplicationFiled: April 20, 2010Publication date: August 12, 2010Applicant: GlycoMimetics, Inc.Inventors: John L. MAGNANI, John T. PATTON, JR., Arun K. SARKAR, Sergei A. SVAROVSKY, Beat ERNST
-
Patent number: 7741312Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof linked to a carbohydrate or glycomimetic.Type: GrantFiled: April 26, 2006Date of Patent: June 22, 2010Assignee: GlycoMimetics, Inc.Inventors: John L Magnani, John T Patton, Jr., Leonard M Williams
-
Patent number: 7728117Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: September 1, 2006Date of Patent: June 1, 2010Assignee: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Publication number: 20100041626Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.Type: ApplicationFiled: February 13, 2009Publication date: February 18, 2010Applicant: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar
-
Publication number: 20090312278Abstract: Methods and medicaments therefor are provided for the treatment of cancers of the blood or a complication therewith in an individual. More specifically, the use of particular glycomimetics for the treatment is described. Methods and medicaments therefor are also provided without regard to cancer type for reducing in an individual the myeloablative bone marrow toxicities of chemotherapy.Type: ApplicationFiled: June 10, 2009Publication date: December 17, 2009Applicant: GlycoMimetics , Inc.Inventors: John L. MAGNANI, John T. PATTON, JR., Theodore A.G. SMITH
-
Patent number: 7517980Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.Type: GrantFiled: August 8, 2006Date of Patent: April 14, 2009Assignee: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar
-
Publication number: 20090036386Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise glycomimetics linked to a compound, for example a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: ApplicationFiled: May 24, 2006Publication date: February 5, 2009Applicant: GlycoMimetics, IncInventors: John L. Magnani, Arun K. Sarkar, John T. Patton, JR.
-
Patent number: 7361644Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a particular glycomimetic linked to a particular BASA (Benzyl Amino Sulfonic Acid).Type: GrantFiled: November 18, 2004Date of Patent: April 22, 2008Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr.
-
Patent number: 7060685Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.Type: GrantFiled: May 16, 2003Date of Patent: June 13, 2006Assignee: GlycoMimetics, Inc.Inventors: John L Magnani, John T Patton, Jr., Leonard M Williams
-
Patent number: 4555530Abstract: Modified benzyl ether-containing resole polyols derived from a phenolic component, a non-aqueous aldehyde, and a halogen-containing aliphatic hydroxyl component are prepared using a metal derivative as a catalyst. These polyols react with organic polyisocyanates to yield closed cell, low friability, low combustibility, rigid polyurethane foams without the need for post curing at elevated temperature. They are also useful in the preparation of modified rigid polyisocyanurate foams.Type: GrantFiled: May 7, 1984Date of Patent: November 26, 1985Assignee: BASF Wyandotte CorporationInventors: John T. Patton, Jr., John P. Rupert
-
Patent number: RE44778Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: May 30, 2012Date of Patent: February 25, 2014Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst